NASDAQ
MEDP

Medpace Holdings Inc

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

Medpace Holdings Inc Stock Price

Vitals

Today's Low:
$277.195
Today's High:
$281.84
Open Price:
$277.61
52W Low:
$141.3
52W High:
$281.84
Prev. Close:
$279.35
Volume:
220902

Company Statistics

Market Cap.:
$8.54 billion
Book Value:
12.825
Revenue TTM:
$1.67 billion
Operating Margin TTM:
19.06%
Gross Profit TTM:
$925.11 million
Profit Margin:
16.06%
Return on Assets TTM:
14.64%
Return on Equity TTM:
79.68%

Company Profile

Medpace Holdings Inc had its IPO on 2016-08-11 under the ticker symbol MEDP.

The company operates in the Healthcare sector and Diagnostics & Research industry. Medpace Holdings Inc has a staff strength of 5,600 employees.

Stock update

Shares of Medpace Holdings Inc opened at $277.61 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $277.2 - $281.84, and closed at $279.54.

This is a +0.07% increase from the previous day's closing price.

A total volume of 220,902 shares were traded at the close of the day’s session.

In the last one week, shares of Medpace Holdings Inc have increased by +2.21%.

Medpace Holdings Inc's Key Ratios

Medpace Holdings Inc has a market cap of $8.54 billion, indicating a price to book ratio of 18.7194 and a price to sales ratio of 4.5628.

In the last 12-months Medpace Holdings Inc’s revenue was $1.67 billion with a gross profit of $925.11 million and an EBITDA of $343.02 million. The EBITDA ratio measures Medpace Holdings Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Medpace Holdings Inc’s operating margin was 19.06% while its return on assets stood at 14.64% with a return of equity of 79.68%.

In Q2, Medpace Holdings Inc’s quarterly earnings growth was a positive 32.2% while revenue growth was a positive 31.2%.

Medpace Holdings Inc’s PE and PEG Ratio

Forward PE
26.9542
Trailing PE
32.5583
PEG
1.97

Its diluted EPS in the last 12-months stands at $8.58 per share while it has a forward price to earnings multiple of 26.9542 and a PEG multiple of 1.97. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Medpace Holdings Inc’s profitability.

Medpace Holdings Inc stock is trading at a EV to sales ratio of 4.9456 and a EV to EBITDA ratio of 23.7841. Its price to sales ratio in the trailing 12-months stood at 4.5628.

Medpace Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.41 billion
Total Liabilities
$852.44 million
Operating Cash Flow
$-8467000.00
Capital Expenditure
$8.45 million
Dividend Payout Ratio
0%

Medpace Holdings Inc ended 2024 with $1.41 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.41 billion while shareholder equity stood at $391.06 million.

Medpace Holdings Inc ended 2024 with $1.10 million in deferred long-term liabilities, $852.44 million in other current liabilities, 306000.00 in common stock, $-371022000.00 in retained earnings and $662.40 million in goodwill. Its cash balance stood at $39.14 million and cash and short-term investments were $39.14 million. The company’s total short-term debt was $55,000,000 while long-term debt stood at $0.

Medpace Holdings Inc’s total current assets stands at $378.93 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $275.06 million compared to accounts payable of $33.61 million and inventory worth $0.

In 2024, Medpace Holdings Inc's operating cash flow was $-8467000.00 while its capital expenditure stood at $8.45 million.

Comparatively, Medpace Holdings Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$279.54
52-Week High
$281.84
52-Week Low
$141.3
Analyst Target Price
$224.75

Medpace Holdings Inc stock is currently trading at $279.54 per share. It touched a 52-week high of $281.84 and a 52-week low of $281.84. Analysts tracking the stock have a 12-month average target price of $224.75.

Its 50-day moving average was $255.62 and 200-day moving average was $219.69 The short ratio stood at 3.23 indicating a short percent outstanding of 0%.

Around 4449.5% of the company’s stock are held by insiders while 8439% are held by institutions.

Frequently Asked Questions About Medpace Holdings Inc

The stock symbol (also called stock or share ticker) of Medpace Holdings Inc is MEDP

The IPO of Medpace Holdings Inc took place on 2016-08-11

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$70.31
0.28
+0.4%
$79.8
-4.2
-5%
$0.42
0.02
+5%
OneSpan Inc (OSPN)
$11.4
-0.07
-0.61%
$33.87
-0.1
-0.29%
$64.73
0.82
+1.28%
$13.04
0.62
+4.99%
$512.55
-13.55
-2.58%
$0
0
+6.25%
Augmedix Inc (AUGX)
$4.94
0.04
+0.82%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Address

5375 Medpace Way, Cincinnati, OH, United States, 45227